(Hypertension. 1999;34:1275.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Department of Medicine (Nephrology), University of Newcastle-on-Tyne, Newcastle-on-Tyne, UK.
Correspondence to Dr T.H. Thomas, Department of Medicine, Medical School, University of Newcastle-on-Tyne, Framlington Place, Newcastle-on-Tyne, NE2 4HH, UK. E-mail T.H.Thomas{at}ncl.ac.uk
AbstractThere is probably a
heterogeneous etiology for essential hypertension (EHT),
and abnormal erythrocyte sodium-lithium countertransport (Na/Li CT) is
common in a subgroup of patients with a strong family history of
hypertension and cardiovascular disease (EHT-FH
patients). The aim of this study was to test the hypothesis that
altering a membrane thiol protein could mimic the abnormal Na/Li CT
observed in the patients and that a more refined understanding of the
mechanism of abnormal Na/Li CT would facilitate a clearer
identification of a subgroup of patients with a homogeneous
biochemical abnormality. Na/Li CT kinetics were determined in untreated
erythrocytes and after thiol group alkylation with
N-ethylmaleimide (NEM). Compared with normal control
erythrocytes, untreated erythrocytes from EHT-FH patients had a low
Km of Na/Li CT, with a high ratio of maximum
velocity to Km. This kinetic pattern was
reproduced in normal erythrocytes by treatment with NEM in sodium-free
medium. The same treatment in EHT-FH erythrocytes caused a markedly
abnormal effect with an increase in maximum velocity, indicating an
increase in transporter turnover in contrast to the increase in sodium
affinity seen in normal control erythrocytes. Frequency distributions
of these kinetic changes showed a subgroup of
75% of EHT-FH
patients with abnormal kinetic changes with NEM. Therefore, the key
Na/Li CT thiol group that is very reactive to NEM and causes the
abnormal Na/Li CT in a subgroup of hypertensive patients may be a
useful intermediate phenotype for a disease group within the
syndrome of EHT. The single flux assay of Na/Li CT at 140 mmol/L
sodium poorly discriminates this group. Identification of the thiol
protein involved may lead to a molecular explanation of the altered
membrane function in this subgroup of patients.
Key Words: erythrocytes hypertension, essential kinetics sodium-lithium countertransport
This article has been cited by other articles:
![]() |
O. Vaccaro, V. Cuomo, M. Trevisan, M. Cirillo, W. Panarelli, M. Laurenzi, M. Mancini, G. Riccardi, and On behalf of the Gubbio Study Research Group Enhanced Na-Li countertransport: a marker of inherited susceptibility to type 2 diabetes Int. J. Epidemiol., October 1, 2005; 34(5): 1123 - 1128. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Dunn, M. Mohteshamzadeh, A. K. Daly, and T. H. Thomas Altered Tropomyosin Expression in Essential Hypertension Hypertension, February 1, 2003; 41(2): 347 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Schork, J. P. Gardner, L. Zhang, D. Fallin, B. Thiel, H. Jakubowski, and A. Aviv Genomic Association/Linkage of Sodium Lithium Countertransport in CEPH Pedigrees Hypertension, November 1, 2002; 40(5): 619 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Mead, R. Wilkinson, and T. H. Thomas Na/Li Countertransport Abnormalities in Type 1 Diabetes With and Without Nephropathy Are Familial Diabetes Care, March 1, 2001; 24(3): 527 - 532. [Abstract] [Full Text] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |